Taiwan's PharmaEngine had a host of good news last week as Merrimack Pharma ($MACK), its U.S. license holder for pancreatic cancer candidate MM-398, was granted priority review by the U.S. FDA and a subsidiary of Baxter ($BAX) also had a filing accepted for the same candidate by the European Medicines Agency that sparked an $11 million payment.
Earlier this month, PharmaEngine submitted a New Drug Application to the Taiwan Food and Drug Administration for MM-398 to treat patients with metastatic adenocarcinoma of the pancreas.
The move followed the NDA and marketing authorization application by its licensing partner, Merrimack Pharmaceuticals in the U.S., and sublicensing partner, Baxter International's BioScience business to the EMA.
The status of the Taiwan application was not listed on the press release or the website.
- here are releases from PharmaEngine (PDF) and Merrimack Pharma
Special Report: Biotech's 5 key attacks on pancreatic cancer - MM-398